Recent studies claim a critical role for RUNX3 in gastric epithelial homeostasis. However, conflicting results exist regarding RUNX3 expression in the stomach and its potential role as a tumour-suppressor gene (TSG) in gastric carcinogenesis. Our aim was to evaluate the role of RUNX3 in early-onset gastric carcinomas (EOGCs). We analysed 41 EOGCs for RUNX3 aberrations using loss of heterozygosity (LOH), fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) analyses. LOH of markers flanking RUNX3 was relatively common, indicating that loss of the gene may play a role in gastric carcinogenesis. However, FISH analysis of selected cases and a panel of 14 gastric carcinoma-derived cell lines showed widespread presence of multiple copies of centromere 1. While RUNX3 copy numbers were generally equal to or fewer than those of centromere 1, at least two copies were present in almost all cells analysed. Accordingly, a subpopulation of tumour cells in 12/37 cases showed RUNX3 protein expression. However, expression was not detected in the adjacent nontumorous mucosa of any case. Together, these observations indicate that chromosome 1 aberrations occur frequently in EOGCs and are reflected in the LOH and IHC patterns found. Our findings refute a role for RUNX3 as a TSG in EOGCs.
Introduction
In spite of the steady decline in its occurrence, gastric carcinoma is the second deadliest malignant neoplasm worldwide (Parkin et al., 1999) . The disease has a high mortality, with a 5-year survival rate of approximately 20% (Jemal et al., 2004) . It is therefore crucial to acquire a better understanding of this disease, and to identify the genes responsible for its onset.
Our group has recently reported a significant percentage of early-onset gastric carcinomas (EOGCs, defined as cases presented earlier than 45 years of age) to show loss of heterozygosity (LOH) at the 1p36 locus (Carvalho et al., 2004) , where a known regulator in major developmental pathways, RUNX3, is found. Instability within this region has been previously reported in the context of gastric carcinoma (Kokkola et al., 1998; Sakakura et al., 1999; Wu et al., 2002) . Interestingly, the 1p36 region has been thought to harbour one or several tumour-suppressor genes (TSGs) for colon cancer, since it was shown that the introduction of a normal human 1p36 chromosome fragment into colon carcinoma cells markedly suppressed their tumorigenicity (Tanaka et al., 1993) .
RUNX3, together with RUNX1 and RUNX2, makes up the RUNX family of genes, which play decisive roles in definitive haematopoiesis, osteogenesis, neurogenesis and thymopoiesis (Okuda et al., 1996; Komori et al., 1997; Inoue et al., 2002; Levanon et al., 2002; Taniuchi et al., 2002; Woolf et al., 2003) . Their dysregulation has been linked to several pathologic conditions, including leukaemia and cleidocranial dysplasia (Lee et al., 1997; Mundlos et al., 1997) . In adults, RUNX3 is mainly expressed in the haematopoietic system with high levels of mRNAs and proteins in spleen, thymus and blood (Bangsow et al., 2001) .
Mouse models have shown the Runx3 protein to form complexes with Smad3 that transmit activin signals, making Runx3 a target in the TGF-b pathway (Hanai et al., 1999; Li et al., 2002) . Further, Runx3 has been shown to be important in murine embryonic development, as Runx3 À/À mice display several neurological, immunological and gastrointestinal defects Levanon et al., 2002; Li et al., 2002; Ehlers et al., 2003; Ito and Miyazono, 2003; Woolf et al., 2003; Brenner et al., 2004; Fainaru et al., 2004) . Noteworthy, all inbred Runx3 À/À mice die at birth, or very soon thereafter.
Recent studies have linked RUNX3 to gastric epithelial homeostasis and gastric carcinogenesis. Li et al. (2002) recently reported the hemizygosity of RUNX3 in gastric cancer specimens, as well as reduction of RUNX3 expression in tumour cells when compared to normal mucosa. Runx3
À/À mice were also generated as part of the study of Li et al. All mice died within 10 days, and their gastric mucosa was found to be hyperplastic. In light of the role of Runx3 in the TGFb pathway (Crawford et al., 1998; Fainaru et al., 2004) , this observation was explained, at least in part, by resistance to the growth-inhibitory activity of TGF-b and to TGF-b-induced apoptosis (Li et al., 2002) . Contrasting results were obtained by Brenner and colleagues. Runx3 À/À mice, generated from a different genetic background (Levanon et al., 2002; Brenner et al., 2004) to that of Li et al., survived for up to 24 months, did not display any early-onset gastric hyperplasia and none went on to develop gastric carcinoma. Additionally, these Runx3-deficient mice registered early-onset colitis, and 80% went on to develop late-onset gastric hyperplasia, which the authors contended to be secondary to the onset of colitis. The authors also reported a lack of expression of RUNX3 in normal gastric mucosa through immunohistochemistry (IHC) and RNA in situ hybridization.
The current study therefore aimed at clarifying the role of RUNX3 in early-onset gastric carcinogenesis.
Results
Based on the results obtained in a previous study (Carvalho et al., 2004) , a panel of 41 EOGCs was used to investigate the role of RUNX3 in gastric carcinogenesis. Detailed patient information is provided in Table 1 . Briefly, all selected cases were microsatellite-stable for (Carvalho et al., 2004) . The results of the LOH analysis for two markers flanking RUNX3 are depicted in Table 2 . Although the panel of EOGCs showed low overall levels of LOH (Carvalho et al., 2004) , the highest percentage was seen for the markers flanking RUNX3: 25% for D1S234 and 17% for D1S1676. Given the above observations, FISH was performed on selected EOGC cases, as well as on a panel of cell lines (derived from patients both younger and older than 45 years), in order to understand more clearly how RUNX3 was affected at the genomic level in gastric tumours. We selected two cases (Y4 and Y11) that were most likely to have true 'losses' of RUNX3 (LOH of both markers flanking the gene), as well as two cases (Y5 and Y102) with retention of both markers, and performed FISH using a RUNX3-specific probe. Three of the four cases (Y5, Y11 and Y102) underwent FACS, ensuring that a highly pure epithelial cell population was analysed. A tumour-rich part of the paraffin section of case Y4 was selected for analysis. A summary of the FISH results is depicted in Table 3. Y102 showed retention of heterozygosity, and FISH analysis confirmed this observation, as most cells presented a centromere 1 : RUNX3 signal ratio (C1 : R3) of 2 : 2. Case Y5 also showed retention of both markers; however, unlike Y102, the C1 : R3 values were 3 : 3 and 4 : 3 in 83.3% of the cells counted (Figure 1a) . Both Y4 and Y11 displayed LOH, and FISH analysis revealed ratios of 3 : 2 and 2 : 1 for Y4, and a ratio of 5 : 3 for Y11.
In an attempt to analyse the RUNX3 status on a broader group of tumours, FISH was subsequently performed on a panel of 14 gastric carcinoma-derived cell lines. Four of the 14 cell lines were derived from patients aged 45 years or younger, and seven cell lines were derived from older patients. The age of three patients from which the respective cell lines were derived is unknown. The results are depicted in Table 4 . Three of the 14 cells lines (one of which was derived from a young patient) presented a predominant C1 : R3 of 2 : 2. The majority of cell lines, however, showed 2-6 copies of centromere 1, and 2-6 copies of RUNX3. In some cases, the number of C1 signals was higher than the number of R3 signals, but at least two copies of RUNX3 were present in all cells counted (Figure 1b) .
We then performed IHC on all cases for which material was available (37/41), in order to investigate the influence of the observed genomic abnormalities on the expression of the RUNX3 protein. Thymus was used as a positive control to validate the RUNX3 antibody (Figure 2a ). To exclude crossreactivity with the Runt domain, a RUNX1-specific antibody was also used. The RUNX3-specific antibody showed expression predominantly in the medulla, whereas RUNX1 expression was mainly observed in the cortex (Figure 2 ). No RUNX3 expression was seen in the adjacent nontumorous gastric epithelium of any case (Table 2, Figures 3 and 4a) , with the exception of very weak cytoplasmatic positivity in deeper specialized glandular cells of the mucosa (Figure 3 ). However, in our experience with a wide variety of antibodies, this is an almost universal occurrence, and is interpreted as negative expression. Further, it contrasted with the strong nuclear positivity in lymphocytes, present in all cases analysed and used as an internal control. In contrast to the surrounding nontumorous epithelium, some weak to moderate nuclear positivity was observed focally in the gastric tumour cell population in 12/37 cases (Table 2, Figure 4b ). The remaining 25 cases showed no RUNX3 positivity in the tumour cells analysed (Table 2) . Table 3 Results of FISH on patient material Most prevalent ratio(s) highlighted in grey Figure 1 Bicolour FISH analysis of a Y5 gastric tumour cell (a) and HM51 nuclear spreads (b) using a centromere 1-specific probe (red) and a RUNX3-specific probe (green) Most prevalent ratio(s) highlighted in grey; ND: not determined Selected cases (13/37, results not shown) were also stained for RUNX1, and expression was detected in both non-neoplastic (notably in the antral pits) and neoplastic gastric epithelium (Figure 4c ). Expression was observed in cells negative for RUNX3 (Figure 4d ).
Discussion
Runx3 biology has been extensively investigated using several strains of Runx3 À/À mice . These studies revealed several cell intrinsic functions of Runx3. In neurogenesis, Runx3 is required for the development and survival of dorsal root ganglia TrkC neurons Levanon et al., 2002) . In thymopoiesis, Runx3 is necessary for the silencing of the CD4 gene during lineage decisions of T cells (Taniuchi et al., 2002; Ehlers et al., 2003; Woolf et al., 2003) . In dendritic cells (DCs), Runx3 functions as a component of the TGF-b signalling cascade . When Runx3 is lost, the knockout DCs do not respond to TGF-b, their maturation is accelerated and accompanied by an increased efficacy to stimulate T cells . The gene has two distinct promoter regions, and it has been demonstrated that their activity is in most cases cell-type specific ).
Conflicting results have recently emerged on the role that RUNX3 plays in gastric carcinogenesis. Li et al. (2002) showed that Runx3 is expressed in the normal murine gastric mucosa, and that Runx3 À/À mice (with a homogeneous C57BL/6 genetic background) developed gastric hyperplasia, which the authors attributed to a loss of function of Runx3 in gastrointestinal tract (GIT) epithelium, resulting in promotion of proliferation and suppression of apoptosis in gastric epithelial cells. The authors therefore postulated Runx3 as a novel TSG in gastric cancer. All Runx3 À/À mice died within 10 days. These observations were linked with the discovery of RUNX3 silencing in about 60% of human gastric cancer specimens analysed (Li et al., 2002) . These results led to several studies being published where the loss of RUNX3 appeared as an important event in gastric carcinogenesis (Ito and Miyazono, 2003; Bae and Choi, 2004; Fukamachi and Ito, 2004; Osaki et al., 2004) . Brenner et al. (2004) , on the other hand, reported that, at E4 weeks of age, Runx3 À/À mice (with a heterogeneous ICR and MF1 genetic background) developed colitis and only at an older age (E8 months) went on to develop gastric mucosal hyperplasia. Further, the mice survived for up to 24 months without developing gastric carcinoma . As Runx3 could not be detected in GIT epithelium Brenner et al., 2004) , but was readily detected in the resident leukocytic population of the GIT, the conclusion reached by Brenner et al. (2004) was that the GIT ailments of the Runx3 À/À mice were a result of the loss of an intrinsic Runx3 cell function in leukocytes. Notably, gastric mucosal hyper- RUNX3 expression is seen predominantly in the medulla, whereas RUNX1 expression is mainly observed in the cortex. Nuclei were visualized by counterstaining with haematoxylin-eosin. Visualization was performed at Â 10 magnification plasia in association with colitis has previously been observed in other mutant mice (Fernandez-Salguero et al., 1997) .
In the present study, we addressed the role of RUNX3 in EOGC. LOH results previously obtained by our group pointed to the possibility of RUNX3 being lost in gastric carcinomas (Carvalho et al., 2004) (Table 2 ). The LOH frequency observed was somewhat lower than that observed by Li et al. (2002) . In an attempt to understand the significance of these observations, FISH was performed on two LOH cases (Y4 and Y11) and on two cases showing retention near the RUNX3 locus (Y5 and Y102) (Table 3) , as well as on a panel of 14 gastric cancer-derived cell lines (Table 4 ). Four out of 14 cell lines were derived from patients younger than 45 years, while seven of the remaining cell lines originated from older patients. The age of three patients from which cell lines were derived is unknown. As it has been previously reported that EOGCs may differ from gastric carcinomas occurring at a later age (Carvalho et al., 2004) , we aimed at extrapolating our findings to a wider group of gastric carcinomas.
The retention cases exhibited a normal C1 : R3 ratio (Y102) and a predominant C1 : R3 ratio of 4 : 3 and 3 : 3 (Y5, Figure 1a) , indicating chromosome 1 duplications or amplifications in most Y5 cells counted. Noteworthy, a previous study using CGH showed gains in the short arm of chromosome 1 in this case (Varis et al., 2003) . Chromosome 1 aberrations were also observed in LOH cases. Various C1 : R3 were seen, with most Y11 cells presenting three or more C1 signals and with every cell retaining at least two copies of RUNX3. For Y4, most cells presented 2-3 C1 signals and two R3 signals, but a minority (17%) of cells showed a C1 : R3 of 2 : 1, suggestive of an actual deletion of RUNX3. This deletion may equally be explained by a gross deletion of the p-arm of chromosome 1.
The FISH results not only explained the observed LOH, but also showed most cells to have at least two copies of RUNX3. It appears, therefore, that the results obtained point to a general chromosome 1 instability and a change of the ratio between maternal and paternal alleles, rather than specific deletions of RUNX3.
The cell lines showed a variety of C1 : R3 ratios, with aneuploidy extensively observed. Although some cell lines show a higher number of C1 signals when compared to R3 signals, no cell line showed counts of fewer than two R3 signals (Figure 1b) . It can thus be concluded that the RUNX3 dosage in tumour cells is at least equal to that of normal cells. No apparent difference was observed between cell lines derived from younger and older patients.
When studying the effect of RUNX3 aberrations on the level of expression of the RUNX3 protein, it was observed that, in accordance to the findings of Groner and colleagues , no RUNX3 expression was detected by IHC in any histologically non-neoplastic gastric epithelial cells (Figures 3 and 4a) . Specifically, no G-cells in the antral mucosa showed any RUNX3 expression (Figure 3a) , despite a recent report that RUNX3 is expressed in a subset of normal gastric epithelial cells, notably in chief cells of fundic glands and in G-cells located in the pyloric portion of the normal stomach (Osaki et al., 2004) . Furthermore, we observed nuclear RUNX3 staining in some tumour cells (Table 2 , Figure 4b ). The lack of expression of RUNX3 in histologically non-neoplastic epithelium, together with occasional expression in tumour cells, precludes a role for RUNX3 as a TSG in EOGC.
It is known that the short arm of chromosome 1 is frequently affected in several types of cancer. Most published results, however, point to the 1p36 region to be amplified, not deleted in gastric carcinomas (Kokkola et al., 1998; Sakakura et al., 1999; Wu et al., 2002) . Studies that do report deletions around 1p36 connect this event to an advanced stage of gastric cancer development, not consistent with early events in gastric carcinogenesis (Sano et al., 1991; Igarashi et al., 2000) . In this context, it is possible that the methylation found in the CpG island of the P2 RUNX3 promoter, as described by Li et al., is caused by increased activity of the DNA methyltransferase 1 in advanced gastric tumours (Etoh et al., 2004) .
In conclusion, we have shown that RUNX3 is unlikely to be a TSG for EOGC, as it is not expressed in histologically non-neoplastic gastric epithelium, and at least two copies of the gene are present in the vast majority of cells analysed. We have also demonstrated that the observed LOH may be explained by the frequent copy number changes that we find due to chromosome 1 aberrations. Further research is needed to determine whether the 1p36 region contains genes that play a significant role in gastric cancer.
Materials and methods

Patient material
Formalin-fixed, paraffin-embedded tissue of 41 gastric carcinomas from patients aged 45 years or younger were retrieved from the Pathology Department of the Academic Medical Centre (Amsterdam, The Netherlands), other hospitals in the Netherlands following a search in a nation-wide database, the Department of Pathology at the Jorvi Hospital (Espoo, Finland) and Johns Hopkins Medical Institute (Baltimore, USA). The tumours were classified by an experienced gastrointestinal pathologist (GJAO) according to the Laure´n classification as intestinal-(n ¼ 10), diffuse-(n ¼ 22) and mixed-type (n ¼ 9) gastric adenocarcinomas. Patient information is depicted in Table 1 . Only case Y11 had a first-degree relative diagnosed with gastric carcinoma.
This study was conducted in accordance with the ethical standards of our institutional medical ethical committee on human experimentation, as well as in agreement with the Helsinki Declaration of 1975, as revised in 1983. cultured in RPMI 1640 (GIBCO BRL, MD, USA) supplemented with 10% foetal calf serum (FCS, GIBCO BRL, MD, USA) and 2% penicillin-streptomycin (GIBCO BRL, MD, USA). Cell lines HM02 and HM51 were cultured in DMEM (GIBCO BRL, MD, USA) supplemented with 10% FCS (GIBCO BRL, MD, USA) and 2% Penicillin-Streptomycin (GIBCO BRL, MD, USA).
Fluorescence in situ hybridization (FISH)
Pretreatment of Y4 paraffin sections was performed as described previously (Haralambieva et al., 2002) .
FACS-sorted cells from paraffin sections of cases Y5, Y11 and Y102 were applied to Superfrost Plus glass slides and airdried overnight at room temperature. The slides were treated with 1 M Na 2 B 4 O 7 for 30 min, washed in phosphatebuffered saline (PBS) pH 7.4, fixed in 1% formalin/PBS for 10 min, washed in PBS, dehydrated and dried.
Nuclear spreads of the 14 cell lines were prepared as described previously (Miki et al., 2004) . The nuclear spreads were airdried and baked overnight at 601C. The slides were treated with 100 mg/ml RNase (Roche, Basel, Switzerland) in 2 Â SSC (standard saline citrate), pH 7.0, for 20 min at 371C, followed by digestion with 0.01% pepsin (Sigma-Aldrich) for 10 min at 371C.
Labelling, hybridization and detection were performed as described previously (Haralambieva et al., 2002) , with the exception of the final probe concentration (30 ng/ml). The probes used were PAC LLNLP704N11132 (RZPD, Berlin, Germany) (RUNX3) and pUC1.77 (centromere 1).
Slides were analysed with a Leica DM5000B fluorescence microscope equipped with filters for FITC, Texas Red and DAPI (Leica). For documentation, images were captured using a Roper Coolsnap Cf digital camera (Cambridge Research Instrumentation, UK) and analysed using Image Pro Plus software version 5.02 (Media Cybernatics, Silver Springs, MD, USA). Hybridization signals were counted from morphologically intact cells, and overlapping nuclei were avoided by counting in areas where individual cells could be identified.
Immunohistochemistry (IHC)
IHC analysis was performed as described previously (Levanon et al., 2002) . Briefly, paraffin sections were incubated with purified RUNX1 and RUNX3 antibodies (1 : 100 and 1 : 1000, respectively) in PBS containing 0.1% Triton X-100 and 3% normal goat serum. PBS containing 0.1% Triton X-100 and 3% normal goat serum. Polyclonal anti-human RUNX3 antibodies were raised in rabbits against a 210-amino-acid fragment spanning part of the carboxy end of the RUNX3 coding region. The protein was generated using the prokaryotic expression vector pRSETB-RUNX3. These anti-RUNX3 antibodies specifically detect RUNX3 proteins of approximately 50 kDa in transfected cells and in human haematopoietic cell lines, both of which show, by Northern blot analysis, expression of RUNX3 (Le et al., 1999) . Biotinylated secondary antibodies. Biotinylated secondary antibodies and Vectastain ABC complex (Vector Lab, Burlingame, CA, USA) were used for signal detection.
